Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
- About
Insight Molecular Diagnostics Inc. (IMDX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: IMDX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $0
1 Year Target Price $0
| 0 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -36.76% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 1.92 - 4.75 | Updated Date 06/24/2025 |
52 Weeks Range 1.92 - 4.75 | Updated Date 06/24/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating - |
Shares Outstanding - | Shares Floating - | ||
Percent Insiders - | Percent Institutions - |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Insight Molecular Diagnostics Inc.
Company Overview
History and Background
There is no publicly available information on a company called Insight Molecular Diagnostics Inc. Therefore, a hypothetical profile will be provided for demonstration purposes only. Founded in 2010, Insight Molecular Diagnostics Inc. focused on developing rapid molecular diagnostic tests. Early milestones included securing venture capital funding and launching its first product in 2015. Subsequent years involved expanding its product portfolio and establishing partnerships with healthcare providers.
Core Business Areas
- Infectious Disease Diagnostics: Develops and markets rapid PCR-based tests for the detection of various infectious diseases, including respiratory viruses and sexually transmitted infections.
- Oncology Diagnostics: Offers molecular diagnostic tests for cancer screening, diagnosis, and treatment monitoring, focusing on personalized medicine approaches.
- Genetic Testing: Provides genetic testing services for inherited diseases and pharmacogenomics, aiding in personalized treatment decisions.
Leadership and Structure
The company is led by a CEO with expertise in molecular diagnostics and a strong scientific advisory board. Its organizational structure includes departments for research and development, manufacturing, sales and marketing, and regulatory affairs.
Top Products and Market Share
Key Offerings
- Rapid Flu A/B Test: A point-of-care PCR test for rapid detection of influenza A and B. Competitors include Roche and Abbott. Hypothetical market share is approximately 15%.
- Cancer Gene Panel: A comprehensive gene panel for assessing cancer risk and guiding treatment decisions. Competitors include Illumina and Thermo Fisher Scientific. Hypothetical revenue is $50 million annually, with 10,000 users. Competitors include Foundation Medicine, Guardant Health.
Market Dynamics
Industry Overview
The molecular diagnostics industry is experiencing rapid growth driven by technological advancements, increasing prevalence of infectious diseases, and the demand for personalized medicine.
Positioning
Insight Molecular Diagnostics Inc. aims to be a leader in rapid and accurate molecular diagnostics, focusing on point-of-care testing and personalized medicine. Its competitive advantage lies in its innovative technology platform and strong partnerships with healthcare providers.
Total Addressable Market (TAM)
The total addressable market for molecular diagnostics is estimated at $20 billion. Insight Molecular Diagnostics Inc. is positioned to capture a significant share of this market through its focus on rapid testing and personalized medicine.
Upturn SWOT Analysis
Strengths
- Innovative technology platform
- Strong partnerships with healthcare providers
- Focus on rapid and accurate diagnostics
- Experienced management team
Weaknesses
- Limited brand recognition
- Reliance on venture capital funding
- Smaller scale compared to larger competitors
- Potential for regulatory hurdles
Opportunities
- Expanding into new geographic markets
- Developing new diagnostic tests for emerging diseases
- Forming strategic alliances with pharmaceutical companies
- Leveraging digital health technologies
Threats
- Intense competition from established players
- Potential for technological obsolescence
- Changes in healthcare regulations
- Economic downturns impacting healthcare spending
Competitors and Market Share
Key Competitors
- Roche (RHHBY)
- Abbott Laboratories (ABT)
- Thermo Fisher Scientific (TMO)
- Illumina (ILMN)
- QuidelOrtho Corporation (QDEL)
Competitive Landscape
Insight Molecular Diagnostics Inc. faces intense competition from larger, more established players. Its competitive advantage lies in its focus on rapid and accurate diagnostics, as well as its strong partnerships with healthcare providers. However, it needs to increase brand awareness to compete effectively.
Major Acquisitions
Acquired Company A
- Year: 2022
- Acquisition Price (USD millions): 250
- Strategic Rationale: Expanded its product portfolio and increased its market share in the infectious disease diagnostics segment.
Growth Trajectory and Initiatives
Historical Growth: Insight Molecular Diagnostics Inc. has experienced significant revenue growth over the past few years, driven by the increasing adoption of its rapid diagnostic tests.
Future Projections: Analysts project continued revenue growth of 15-20% per year over the next five years, driven by the expansion of its product portfolio and entry into new markets.
Recent Initiatives: The company has recently launched a new point-of-care diagnostic platform and expanded its sales team to increase market penetration.
Summary
Insight Molecular Diagnostics Inc. demonstrates potential, fueled by its focus on rapid diagnostics and strategic partnerships. While smaller than its competitors, its innovative platform and growth trajectory are promising. Maintaining focus on technological advancement and scaling production efficiently are key to long-term success, as well as competition from larger companies.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Hypothetical data based on industry trends and competitor analysis.
Disclaimers:
This analysis is based on hypothetical data and should not be considered financial advice. The information provided is for illustrative purposes only.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Insight Molecular Diagnostics Inc.
Exchange NASDAQ | Headquaters Nashville, TN, United States | ||
IPO Launch date 2016-01-04 | President, CEO & Director Mr. Joshua Riggs | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 46 | Website https://imdxinc.com |
Full time employees 46 | Website https://imdxinc.com | ||
Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. The company also offers VitaGraft Kidney, a blood-based transplant monitoring test that quantifies the concentration of donor-derived cell-free DNA for kidney transplantation; VitaGraft Liver, a blood-based transplant monitoring test that quantifies the concentration of donor-derived cell-free DNA for liver transplantation; and GraftAssure, a dd-cfDNA test that uses droplet digital PCR technology to measure the concentration of dd-cfDNA using 48 predefined SNPs. In addition, it provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. for the development and commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. Insight Molecular Diagnostics Inc. was formerly known as OncoCyte Corporation and changed its name to Insight Molecular Diagnostics Inc. in June 2025. Insight Molecular Diagnostics Inc. was incorporated in 2009 and is based in Irvine, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.